Objective To evaluate the efficacy of donepezil combined with butylphthalide in the treatment of Alzheimer's disease(AD)through meta-analysis,and to explore its potential mechanism.Methods Computerized searches were conducted in the databases of CNKI,Wanfang,PubMed,International Clinical Trials Registry Platform(ICTRP),and The Cochrane Library from the establishment of the database to March 2023 for literature related to the treatment of AD with Donepezil combined with Butylphthalide(hereinafter referred to as the combined treatment group).Revman 5.4 software was used for meta-analysis.Results In this study,a total of 14 randomized controlled trials were included,with 630 patients in the combined treatment group and 638 patients in the control group(Donepezil alone).The meta-analysis results showed that compared with the control group,the combined treatment group had statistically significant differences in total efficacy,mini-mental state examination(MMSE)score,Alzheimer's disease assessment scale-cognitive subscale(ADAS-cog)score,and breath holding index(BHI)(P＜0.001).There was no significant difference in the incidence of adverse reactions between the two groups(P=0.53).Conclusion Compared with donepezil alone,donepezil combined with butylphthalide has better efficacy in the treatment of AD.However,due to the inclusion of a small number of single-center research articles and short follow-up time,the above conclusions still need to be confirmed by large-scale,high-quality randomized controlled trials.
维普
万方数据